The Latest Cardiac and Vascular News
SEOUL, South Korea and BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (Mezzion Pharma) announces that new data from its Phase 3 efficacy and safety trial (FUEL Trial) and its open label extension trial (FUEL OLE Trial) that concerns the treatment of a very large subgroup of patients with congenital single ventricle […]
Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) voluntarily ended early by the Company in order to evaluate existing program data and determine next steps forward Company to reprioritize resources and capital towards successful commercialization of bentracimab and advancement of other pipeline programs MALVERN, Pa. & SAN DIEGO–(BUSINESS […]
Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer) in high risk patient population with heart failure Results suggest that treatment with Veltassa® is beneficial in heart failure patients to control serum potassium levels Veltassa® enabled 85% of patients to be optimized to […]
IRVINE, Calif., Dec. 20, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with severe pulmonary regurgitation. The Edwards SAPIEN 3 […]
Quantification of the structure and composition of the vessel wall and assessment of lipid-rich necrotic core plaque (CPT 0710T-0713T) BOSTON–(BUSINESS WIRE)–Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial intelligence to enable the precise diagnosis and treatment of the world’s leading cause of death announced a new CPT […]
SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus (AAV) gene therapies to […]
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., announced today that it received approval from a Competent Authority in Poland to conduct initial patient implants with its Optimum Transcatheter Aortic Valve Implantation (TAVI) system™. The Company will sponsor this CE Mark-enabling pilot study on patients with severe Aortic Stenosis and begin to […]
The ESC Heart Failure Journal shares additional results from FAST BioMedical’s EMPAKT CHF clinical study. INDIANAPOLIS (Dec. 10, 2021) — FAST BioMedical (FAST), a privately held late clinical-stage medical technology company, today announces theEuropean Society of Cardiology (ESC) Heart Failure Journal has published additional results from its fourth human […]
ONLY HOSPITAL IN COACHELLA VALLEY TO OFFER TAVR RANCHO MIRAGE, Calif., Dec. 16, 2021 /PRNewswire/ — Eisenhower Health is the FIRST hospital in California to be recognized by Edwards Lifesciences for completing its Edwards Benchmark program for the treatment of aortic stenosis in patients undergoing transcatheter aortic valve replacement (TAVR). The standard treatment for aortic […]
MILWAUKEE, Dec. 14, 2021 /PRNewswire/ — Mpirik, an A.I. healthcare technology company that develops automated patient screening models for cardiovascular disease to drive actionable insights, quality and research, has published research in the Annals of Thoracic Surgery about their screening success. The study looked at undertreatment of aortic stenosis, a cardiovascular disease with […]
